AZAFAROS B.V.

Azafaros B.V. is a biotechnology company based in The Netherlands, focusing on developing new treatment options for patients with rare genetic metabolic disorders. Founded in 2018 by a team of experienced industry professionals and scientists, the company is dedicated to addressing rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. The company's proprietary lead compound, nizubaglustat, is poised to address inherited life-threatening lysosomal storage diseases for which there are currently no effective therapies. This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging its team's expertise and partnerships in orphan drug development, Azafaros is advancing its lead program in the clinic and expanding its product pipeline into other rare metabolic diseases through its drug discovery efforts. In February 2020, Azafaros secured a €25.00M Series A investment from prominent investors including BioGeneration Ventures, Forbion, and BioMed Partners. The company's innovative approach and commitment to addressing unmet medical needs in the realm of rare metabolic disorders position it as a noteworthy player in the biotechnology and healthcare industries.